You just read:

FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications

News provided by

Amplyx Pharmaceuticals

Sep 09, 2019, 08:00 ET